Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Therakos Holdings Usa LLC is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is assigned to ALLEN, MARIANNE P. As the busiest examiner for the company, ALLEN, MARIANNE P is managing 1 pending action, which accounts for the entire active workload. This prosecution is centralized within 1 distinct examiner and 1 distinct art unit, reflecting a focused technical scope.
The 1 pending office action in Biotechnology & Pharmaceuticals indicates a specific point of engagement with the USPTO. Since there is 1 distinct art unit involved, the company's current application is being reviewed within a single specialized group. The busiest examiner, ALLEN, MARIANNE P, holds 1 pending action, matching the total number of pending office actions for the portfolio. This alignment means the company's current outcomes in this technology area are tied to the 1 distinct examiner currently assigned.
Practitioners should note that the 1 distinct examiner and 1 distinct art unit provide a singular channel for the company's current intellectual property efforts. With 1 pending office action, there is no current distribution of work across different examiners or units. This concentration under ALLEN, MARIANNE P underscores the importance of this examiner's specific review process for the 1 pending office action currently in the pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392250 | ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS | ALLEN, MARIANNE P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392250 | ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392250 | ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS | ALLEN, MARIANNE P | 1647 | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTherakos Holdings Usa LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marianne P Allen has the most, with 1 of Therakos Holdings Usa LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.